标题
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-05-23
DOI
10.3389/fimmu.2022.886546
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
- (2022) Yupanun Wutti-in et al. Frontiers in Oncology
- Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
- (2022) Jing Guo et al. Frontiers in Cell and Developmental Biology
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
- (2021) Agrima Mian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells
- (2021) Alka Dwivedi et al. MOLECULAR CANCER THERAPEUTICS
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
- (2021) Darel Martínez Bedoya et al. Frontiers in Immunology
- Delivery technologies for T cell gene editing: Applications in cancer immunotherapy
- (2021) Ella S. Atsavapranee et al. EBioMedicine
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.
- (2021) Bijal D. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- The antigen‐binding moiety in the driver's seat of CARs
- (2021) Heleen Hanssens et al. MEDICINAL RESEARCH REVIEWS
- Tisagenlecleucel Immunogenicity in Relapsed/Refractory Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
- (2021) Karen Thudium Mueller et al. Blood Advances
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Autologous CAR T-cell therapies supply chain: challenges and opportunities?
- (2020) Maria M. Papathanasiou et al. CANCER GENE THERAPY
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
- (2020) Norris Lam et al. Nature Communications
- EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma
- (2020) Irene Papadouli et al. ONCOLOGIST
- Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
- (2020) Leila Jafarzadeh et al. Frontiers in Immunology
- CAR-T design: Elements and their synergistic function
- (2020) Jayapriya Jayaraman et al. EBioMedicine
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
- (2019) Dwivedi Alka et al. Frontiers in Immunology
- Engineering and Design of Chimeric Antigen Receptors
- (2019) Sonia Guedan et al. Molecular Therapy-Methods & Clinical Development
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
- (2019) Boris Gorovits et al. BIODRUGS
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies
- (2019) Yu Zhao et al. CLINICAL CANCER RESEARCH
- Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Rakesh Popat et al. BLOOD
- Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
- (2019) David A Sallman et al. BLOOD
- Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia
- (2019) Cheng Qian et al. CLINICAL CANCER RESEARCH
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- A generic cell surface ligand system for studying cell–cell recognition
- (2019) Eleanor M. Denham et al. PLOS BIOLOGY
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
- (2018) Timothy M. Pierpont et al. Frontiers in Oncology
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
- (2018) Kevin A. Hay BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- Fully human CD19-specific chimeric antigen receptors for T-cell therapy
- (2017) D Sommermeyer et al. LEUKEMIA
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
- (2017) Leah Alabanza et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
- (2016) Qiong J. Wang et al. CLINICAL CANCER RESEARCH
- Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
- (2016) Alfredo Perales-Puchalt et al. CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
- (2016) Yozo Nakazawa et al. Journal of Hematology & Oncology
- 247. Phase I Study of Second Generation Chimeric Antigen Receptor-Engineered T Cells Targeting IL13Rα2 for the Treatment of Glioblastoma
- (2016) Christine E. Brown et al. MOLECULAR THERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- The Global Burden of Cancer 2013
- (2015) Christina Fitzmaurice et al. JAMA Oncology
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation
- (2013) Eric Spierings et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
- (2013) H. Torikai et al. BLOOD
- Cancer in developing countries: The next most preventable pandemic. The global problem of cancer
- (2013) Miriam López-Gómez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering
- (2013) Sandrine Boissel et al. NUCLEIC ACIDS RESEARCH
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- Genetically Modified T cells Targeting Interleukin-11 Receptor -Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases
- (2011) G. Huang et al. CANCER RESEARCH
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- The immunogenicity of humanized and fully human antibodies
- (2010) Fiona A. Harding et al. mAbs
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More